Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

Jeffrey H. Kordower, Stéphane Palfi, Er-Yun Chen et al. · Annals of Neurology · 1999 · 389 citations

Medicine, Neurology, Neuroscience +17

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease

Maurizio Scarpa, Zsuzsanna Almássy, Michael Beck et al. · Orphanet Journal of Rare Diseases · 2011 · 231 citations · Full text

Life Sciences, Neurology, Pathology +17

Initial report from the Hunter Outcome Survey

J. E. Wraith, Michael Beck, Roberto Giugliani et al. · Genetics in Medicine · 2008 · 190 citations

Life Sciences, Internal Medicine, Pathology +15

Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid

Patricia Dickson, Michael F. McEntee, Carole Vogler et al. · Molecular Genetics and Metabolism · 2007 · 162 citations · Full text

Medicine, Neurology, Neurosurgery +8

Japan Elaprase® Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)

Torayuki Okuyama, Akemi Tanaka, Yasuyuki Suzuki et al. · Molecular Genetics and Metabolism · 2009 · 146 citations

Life Sciences, Biochemistry, Pharmacotherapy +13